Quantcast

Latest linezolid Stories

fa47caadba9878170f61f55fb03e57c11
2008-10-27 07:40:00

Two new forms of experimental drugs may battle a dangerous form of evolving infection, according to researchers.

2008-10-26 12:00:20

Targanta Therapeutics Corporation (NASDAQ: TARG) today announced the presentation of key clinical findings of its lead antibiotic drug candidate, oritavancin, at the combined annual meetings of the 48th Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC) and the 46th Infectious Disease Society of America (IDSA), taking place in Washington, DC.

2008-10-26 12:00:10

BOSTON, Oct. 26 /PRNewswire/ -- Paratek Pharmaceuticals, Inc. today announced positive Phase 2 data for the Company's lead antibiotic, PTK 0796, a first-in-class aminomethylcycline (AMC).

2008-10-26 12:00:10

NEW HAVEN, Conn., Oct. 26 /PRNewswire/ -- Rib-X Pharmaceuticals, Inc.

2008-10-25 12:00:17

Targanta Therapeutics Corporation (NASDAQ: TARG) today announced the presentation of studies detailing oritavancin's superior in vitro potency at the combined annual meetings of the Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC) and the Infectious Disease Society of America (IDSA), taking place in Washington, DC.

2008-10-25 12:00:05

Targanta Therapeutics Corporation (NASDAQ: TARG) today released the in vivo data from a preclinical study comparing the activity of its antibiotic drug candidate, oritavancin, to vancomycin in a hamster model of Clostridium difficile infection.

2008-10-22 09:00:42

Targanta Therapeutics Corporation (Nasdaq: TARG) today announced initial efficacy and safety results from its Phase 2 clinical study investigating oritavancin at Single or Infrequent Doses for the Treatment of Complicated Skin and Skin Structure Infections (cSSSI), or SIMPLIFI.

2008-10-20 09:00:42

NEW HAVEN, Conn., Oct. 20 /PRNewswire/ -- Rib-X Pharmaceuticals, Inc.


Latest linezolid Reference Libraries

0_4d46cc72a490344d44ba78359f528175
2011-04-26 21:07:20

Enterococcus is a Gram-positive, commensal bacterium inhabiting the gastrointestinal tracts of humans and other mammals. It is a main constituent of some probiotic food supplements. E. faecalis can cause life-threatening infections in humans, especially in the nosocomial environment, where the naturally high levels of antibiotic resistance found in E. faecalis contribute to its pathogenicity. It is frequently found in root canal-treated teeth in prevalence values ranging from 30% to 90% of...

0_71ad70ea6f0948a7e84406e760c7f5a4
2011-04-15 14:36:05

Enterococcus faecalis "“ formerly classified as part of the Group D Streptococcus system "“ is a Gram-positive, commensal bacterium inhabiting the gastrointestinal tracts of humans and other mammals. It is one of the main constituents of some probiotic food supplements. E. faecalis can cause life-threatening infections in humans. It is frequently found in root canal-treated teeth in prevalence values ranging from 30% to 90% of the cases. It is a non-motile, facultatively anaerobic...

More Articles (2 articles) »